Top Markets
Coin of the day
Amarantus BioScience Holdings, Inc. Amarantus BioScience Holdings, Inc.

Amarantus BioScience Holdings, Inc.

AMBS
Rang in aandelen #41184
Amarantus BioScience Holdings, Inc. operates as a biopharmaceutical firm,... Amarantus BioScience Holdings, Inc. operates as a biopharmaceutical firm, concentrating on creating innovative diagnostic tools and therapeutic solutions. Its primary focus areas encompass neurological disorders, psychiatric conditions, eye-related ailments (ophthalmology), and regenerative medicine. The company's diagnostic pipeline includes the LymPro test, a blood-based diagnostic designed to detect Alzheimer's disease by analyzing lymphocyte proliferation, and MSPrecise, a proprietary DNA sequencing assay aimed at identifying individuals with multiple sclerosis. On the therapeutic front, Amarantus is advancing Eltoprazine, a small molecule drug targeting both Levadopa-Induced Dyskinesia in Parkinson's patients and attention deficit hyperactivity disorders (ADHD). Additionally, they are developing a mesencephalic-astrocyte-derived neurotrophic factor (MANF) for treating conditions modeled in animals, such as retinitis pigmentosa and retinal artery occlusion. Amarantus also maintains several specialized platforms: NuroPro, a diagnostic platform dedicated to neurodegenerative diseases with an initial application in Parkinson's; BC-SeraPro, an oncology diagnostic platform specifically for breast cancer; and the PhenoGuard platform, designed for discovering new neurotrophic factors. Beyond these, the company is progressing with Engineered Skin Substitute (ESS), a cell therapy-based product for autologous skin replacement, currently in mid-stage clinical development for severe, life-threatening burns. The company has established a collaborative research and development agreement with both the U.S. Army Institute of Surgical Research and Rutgers University. Established in 2008, Amarantus BioScience Holdings, Inc., which previously operated as Amarantus Bioscience, Inc. until its name change in April 2013, is headquartered in New York, New York.
Aandeelprijs
$0.0001
Laatst gesynchroniseerd: 2026-08-11
Marktkapitalisatie
$36.84K
Verandering (1 dag)
0.00%
Verandering (1 jaar)
-66.67%
Land
US
Handel Amarantus BioScience Holdings, Inc. (AMBS)

Categorie

Omzet van Amarantus BioScience Holdings, Inc. (AMBS)
Omzet in Aug 2026 TTM: 0
Volgens de laatste financiële rapporten van Amarantus BioScience Holdings, Inc. bedraagt de huidige omzet van het bedrijf (TTM) 0. In 2026 behaalde het bedrijf een omzet van 0 gelijk aan de omzet in het jaar 2026, die 0 bedroeg. De omzet is het totale bedrag aan inkomsten dat een bedrijf genereert door de verkoop van goederen of diensten. In tegenstelling tot de winst worden er geen kosten afgetrokken.
Omzetgeschiedenis van Amarantus BioScience Holdings, Inc. van 2026 tot 2026
Omzet aan het einde van elk jaar
Jaar Omzet Wijzigen
Niet genoeg gegevens voor de verstrekte datums.
Omzet van vergelijkbare bedrijven of concurrenten
Bedrijf Omzet Omzetverschil Land
$12.62B -
US
$6.02B -
NL
- -
CH
- -
KR
$10.11B -
BE